124
Participants
Start Date
April 30, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
June 30, 2027
OCTA-C1-INH
OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
Placebo
0.1 mL/kg BW 0.9% sodium chloride injection
RECRUITING
Octapharma Research Site, Sofia
RECRUITING
Octapharma Research Site, Kragujevac
WITHDRAWN
Octapharma Research Site, Lima
NOT_YET_RECRUITING
Octapharma Research Site, Lima
RECRUITING
Octapharma Research Site, Toledo
RECRUITING
Octapharma Research Site, Farmington Hills
RECRUITING
Octapharma Research Site, Lviv
NOT_YET_RECRUITING
Octapharma Research Site, Lviv
RECRUITING
Octapharma Research Site, Centennial
RECRUITING
Octapharma Research Site, Cluj-Napoca
NOT_YET_RECRUITING
Octapharma Research Site, Tirana
NOT_YET_RECRUITING
Octapharma Research Site, Rosario
RECRUITING
Octapharma Research Site, Yerevan
NOT_YET_RECRUITING
Octapharma Research Site, Lima
NOT_YET_RECRUITING
Octapharma Research Site, Podgorica
NOT_YET_RECRUITING
Octapharma Research Site, Lima
NOT_YET_RECRUITING
Octapharma Research Site, Ankara
NOT_YET_RECRUITING
Octapharma Research Site, Istanbul
NOT_YET_RECRUITING
Octapharma Research Site, Izmir
NOT_YET_RECRUITING
Octapharma Research Site, Sakarya
NOT_YET_RECRUITING
Octapharma Research Site, Mexico City
RECRUITING
Octapharma Research Site, Kyiv
Lead Sponsor
Octapharma
INDUSTRY